Filing Details

Accession Number:
0001012975-10-000008
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-01-13 12:00:00
Reporting Period:
2010-01-11
Filing Date:
2010-01-13
Accepted Time:
2010-01-13 17:50:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070336 Achillion Pharmaceuticals Inc ACHN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1166285 Michael Steinmetz C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1249153 Dennis Henner C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252522 Nicholas Galakatos C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252523 Robert Liptak C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252525 Kurt Wheeler C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431403 Nicholas Simon C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
Yes No Yes No
1431408 Jeffrey Leiden C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431437 Clarus Ventures Ii, Llc C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431439 Clarus Ventures Ii Gp, L.p. C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431443 Clarus Lifesciences Ii, L.p. C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-01-11 233,990 $3.77 4,386,577 No 4 S Indirect By Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Fund
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plan adpoted by Clarus Lifesciences II, L.P. (the "Fund") on November 1, 2009.
  2. Securities held of record by the Fund. Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of the Fund, may be deemed to beneficially own certain of the shares held of record by the Fund. The GPLP disclaims beneficial ownership of all shares held of record by the Fund in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Messrs. Galakatos, Henner, Leiden, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Messrs. Galakatos, Henner, Leiden, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by the Fund in which he does not have an actual pecuniary interest.